INTS has been in the news 900% more than usual
Oct 30, 2025, 6:34 PM
0.00%
INTS has been in the news recently: Intensity Therapeutics, Inc. reported a 75% disease control rate in its phase 1/2 study of INT230-6 for advanced cancer, with a webinar scheduled for October 31, 2025. The company also experienced a significant increase in revenue, reaching $5 million, attributed to strong sales in their new product line.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.